Antagonists of the serotonin receptor 2B (5-HT2B) have shown great promise as therapeutics for the treatment of pulmonary arterial hypertension, valvular heart disease, and related cardiopathies. Herein, we describe a high-throughput screen campaign that led to the identification of highly potent and selective 5-HT2B antagonists. Furthermore, selected compounds were profiled for their predicted ability to cross the blood–brain barrier. Two exemplary compounds, VU0530244 and VU0631019, were predicted to have very limited potential for brain penetration in human subjects, a critical profile for the development of 5-HT2B antagonists devoid of centrally-mediated adverse effects.
Get full access to this article
View all access options for this article.
References
1.
SetolaV, RothBL. The Emergence of Serotonin 5-HT2B Receptors as DRUG Antitargets. In: Antitargets: Prediction and Prevention of Drug Side Effects. (Vaz RJ, Klabunde T. eds.) Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany; 2008.
2.
HuangXP, SetolaV, YadavPM, et al.Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2b receptor agonists: Implications for Drug Safety Assessment. Mol Pharmacol, 2009; 76(4):710–722; doi: 10.1124/mol.109.058057
3.
RothmanRB, BaumannMH, SavageJE, et al.Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 2000; 102:2836–2841; doi: 10.1161/01.CIR.102.23.2836
4.
LaunayJM, HervéP, Peoc'hK, et al.Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med, 2002; 8:1129–1135; doi: https://doi.org/10.1038/nm764
5.
PorterMR, XiaoH, WangJ, et al.3-Amino-chromanes and tetrahydroquinolines as selective 5-HT2B, 5-HT7, or σ1 receptor ligands. ACS Med Chem Lett, 2019; 10(10):1436–1442; doi: 10.1021/acsmedchemlett.9b00225
6.
DosaPI, WardT, WaltersMA, et al.Synthesis of novel analogs of cabergoline: Improving cardiovascular safety by removing 5-HT2B receptor agonism. ACS Med Chem Lett, 2013; 4(2):254–258; doi: 10.1021/ml3003814
7.
StolaV, RothBL. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: Focus on ‘fen–phen’. Expert Opin Drug Metab Toxicol, 2005; 1(3);377–387; doi: DOI: 10.1517/17425255.1.3.377
LaunayJM, HervéP, CallebertJ, et al.Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood, 2012; 119(7):1772–1780; doi: 10.1182/blood-2011-06-358374
11.
SetolaV, HufeisenSJ, Grande-AllenJ, et al.3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol, 2003; 63(6):1223–1229; doi: 10.1124/mol.63.6.1223
12.
SchadeR, AndersohnF, SuissaS, et al.Dopamine agonists and the risk of cardiac-valve regurgitation. N Eng J Med, 2007; 356; 29–38; doi: 10.1056/NEJMoa062222
13.
BloodworthNC, WestJD, MerrymanWD. Microvessel mechanobiology in pulmonary arterial hypertension: Cause and effect. Hypertension, 2015; 65:483–489; doi: 10.1161/HYPERTENSIONAHA.114.04652
ThenappanT, OrmistonML, RyanJJ, et al.Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ, 2018; 360:j5492; doi: 10.1136/bmj.j5492
16.
SutendraG, MichelakisED. Pulmonary arterial hypertension: Challenges in translational research and a vision for change. Sci Transl Med, 2013; 5:208sr5–208sr5.
17.
MarcH, OlivierS, GéraldS. Treatment of pulmonary arterial hypertension. N Engl J Med, 2004; 12; doi: 10.1056/NEJMra040291
18.
EddahibiS, HanounN, LanfumeyL, et al.Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest, 2000; 105:1555–1562; doi: 10.1172/JCI8678
19.
PopovaNK, TsybkoAS, NaumenkoVS. The implication of 5-HT receptor family members in aggression, depression and suicide: Similarity and difference. Int J Mol Sci, 2022; 23; 8814; doi: 10.3390/ijms23158814
20.
PopaD, LénaC, FabreV, et al.Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors. J Neurosci, 2005; 25(49);11231–11238; doi: 10.1523/JNEUROSCI.1724-05.2005
21.
BevilacquaL, DolyS, KaprioJ, et al.A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature, 2010; 468; 1061–1066; doi: 10.1038/nature09629
22.
RodriguezAL, GrierMD, JonesCK, et al.Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol, 2010; 78(6);1105–1123. doi: 10.1124/mol.110.067207
23.
FengB, MillsJB, DavidsonRE, et al.In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos, 2008; 36(2):268–275; doi: 10.1124/dmd.107.017434
